Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Invesco Ltd.

Invesco Ltd. decreased its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 35.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 204,890 shares of the medical device company's stock after selling 112,695 shares during the period. Invesco Ltd. owned about 0.31% of Tandem Diabetes Care worth $7,380,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in TNDM. JPMorgan Chase & Co. lifted its holdings in Tandem Diabetes Care by 134.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 197,583 shares of the medical device company's stock valued at $8,379,000 after buying an additional 113,355 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in shares of Tandem Diabetes Care by 163.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,775 shares of the medical device company's stock valued at $65,000 after acquiring an additional 1,101 shares in the last quarter. US Bancorp DE boosted its holdings in shares of Tandem Diabetes Care by 15.2% in the fourth quarter. US Bancorp DE now owns 38,708 shares of the medical device company's stock valued at $1,394,000 after purchasing an additional 5,108 shares during the period. KBC Group NV grew its stake in Tandem Diabetes Care by 41.5% in the fourth quarter. KBC Group NV now owns 192,479 shares of the medical device company's stock worth $6,933,000 after purchasing an additional 56,461 shares in the last quarter. Finally, Envestnet Portfolio Solutions Inc. increased its holdings in Tandem Diabetes Care by 22.0% during the 4th quarter. Envestnet Portfolio Solutions Inc. now owns 6,560 shares of the medical device company's stock worth $236,000 after purchasing an additional 1,184 shares during the period.

Tandem Diabetes Care Stock Performance

Shares of Tandem Diabetes Care stock traded down $0.59 on Monday, reaching $17.47. 1,140,892 shares of the stock were exchanged, compared to its average volume of 1,503,446. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -9.05 and a beta of 1.52. The business has a 50 day moving average price of $20.17 and a two-hundred day moving average price of $29.17. Tandem Diabetes Care, Inc. has a twelve month low of $15.75 and a twelve month high of $53.69. The company has a quick ratio of 2.32, a current ratio of 2.90 and a debt-to-equity ratio of 1.29.

Analyst Upgrades and Downgrades

TNDM has been the topic of a number of recent research reports. Canaccord Genuity Group reissued a "buy" rating and set a $63.00 price target on shares of Tandem Diabetes Care in a research report on Wednesday, February 26th. Robert W. Baird reduced their price target on shares of Tandem Diabetes Care from $37.00 to $33.00 and set a "neutral" rating for the company in a report on Thursday, February 27th. Sanford C. Bernstein downgraded shares of Tandem Diabetes Care from an "outperform" rating to a "market perform" rating and dropped their price objective for the company from $35.00 to $25.00 in a research note on Friday, February 28th. Mizuho initiated coverage on shares of Tandem Diabetes Care in a research note on Thursday, April 10th. They issued a "neutral" rating and a $20.00 price objective for the company. Finally, Citigroup cut Tandem Diabetes Care from a "buy" rating to a "neutral" rating and dropped their target price for the company from $35.00 to $24.00 in a research report on Tuesday, March 4th. Eight analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, Tandem Diabetes Care has an average rating of "Moderate Buy" and a consensus price target of $43.81.

Insider Activity

In related news, COO Jean-Claude Kyrillos purchased 10,538 shares of the company's stock in a transaction dated Friday, March 7th. The stock was acquired at an average cost of $18.12 per share, for a total transaction of $190,948.56. Following the completion of the transaction, the chief operating officer now directly owns 10,538 shares of the company's stock, valued at approximately $190,948.56. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 1.90% of the company's stock.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.